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Abstract
Purpose Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and 
retinal thickness when treated with bevacizumab injection frequencies of 6 or 8 weeks compared to 4 weeks. This study 
aimed to investigate this non-inferiority in quality of life (QoL). We hypothesized that less frequent bevacizumab injections 
are not inferior regarding patients reported QoL.
Methods Patients were randomized to bevacizumab every 4 (n = 64), 6 (n = 63), and 8 weeks (n = 64). Patients were at least 
65 years old, have a best-corrected visual acuity of 20/200 to 20/20, no previous ARMD treatment and active leakage. Vision-
related QoL questionnaire NEI VFQ-39 was used to assess QoL at baseline and after 1 year. General QoL questionnaire 
SF-36 was included for secondary analysis. Multilevel analyses were performed, correcting for age, gender and baseline.
Results The 6 (3.68; 95% CI − 0.63 to 8.00) and 8 (2.15; 95% CI − 2.26 to 6.56) weeks bevacizumab regimens resulted in 
non-inferior QoL differences compared to 4 weeks on the NEI VFQ-39. Also on the SF-36 the differences were well within 
the non-inferiority limits.
Conclusion Non-inferiority of the 6 and 8 weeks frequencies was demonstrated compared to 4 weeks on vision-related 
and general QoL in patients with nARMD. These results are in line with previously published results of lower frequency 
injections regarding visual acuity and central retinal thickness. Lower injection frequency may reduce burden, side effects, 
and treatment costs. In consideration of these results, 8 weeks frequency injections of intravitreal bevacizumab could be 
considered in patients with nARMD.
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Introduction
Age-related macular degeneration (ARMD) is the leading 
cause of severe vision loss and blindness among people aged 
over 50 years in Western countries [1, 2]. ARMD affects 
central retinal function, profoundly impairing the patient’s 
ability to perform daily activities and their quality of life 
(QoL) [3]. Exudative ARMD, an aggressive form of ARMD 
[4, 5], progresses rapidly and is characterized by the devel-
opment of choroidal neovascularization (CNV); hence, it 
is often described as neovascular ARMD (nARMD). The 
current standard therapy for nARMD is intravitreal injec-
tion of anti-vascular endothelial growth factor (VEGF), a 
treatment which improves the visual prognosis of nARMD 
patients considerably.
To enhance effective patient-centered care, there is a trend 
toward gathering outcome information from the patient’s per-
spective in addition to the clinical outcomes. Since there is 
interest in the patients’ perspective of satisfaction, in terms of 
outcome, several patient-reported outcome measures (PROMs) 
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have been developed [6]. Several studies have suggested that 
the use of PROMs have a positive effect on the doctor-patient 
communication, and consequently patients’ satisfaction [7].
The most commonly used anti-VEGF medications are 
ranibizumab, aflibercept and bevacizumab. The efficacy of 
ranibizumab and aflibercept has been proven and appear 
clinically equivalent, and are approved both by the Food 
and Drug Administration (FDA) and the European Medi-
cines Agency (EMA) for intraocular use in nARMD [8–13]. 
Bevacizumab has been approved by the FDA and the EMA 
for the treatment of various tumors, such as colorectal cancer 
[14], but not specifically for nARMD. However, in recent 
years, ophthalmologists have been prescribing bevacizumab 
for off-label use in nARMD because it is a cost-effective 
substitute for ranibizumab and aflibercept [15–20]. Multiple 
studies provided RCT evidence supporting the efficacy of 
bevacizumab in a monthly, pro re nata and treat-and-extend 
regimes [15–20]. The CATT study also showed that there 
is no difference in effectiveness in term of vision and side 
effects between ranibizumab and bevacizumab and is com-
parably effective when the injection frequency is 4 weeks. 
Moreover, the IVAN study showed similar results on QoL 
for bevacizumab and ranibizumab measured with the Euro-
Qol-5D [21], macular disease-specific quality of life [22] 
and treatment satisfaction [23].
The every-four-weeks regimen used in the CATT study 
was chosen for bevacizumab based on prior ranibizumab 
trials and is a widely adopted and proven strategy. How-
ever, the relatively long half-life of bevacizumab might allow 
the achievement of a therapeutic effect with less frequent 
injections, as has been the experience in the clinic [24, 25]. 
Reduced numbers of injections could have several benefi-
cial effects, including a decrease in the risks associated with 
intravitreal injection (such as endophthalmitis and retinal 
detachment), improved cost-effectiveness, reduced patient 
burden, and a reduced ophthalmic work-load. A study in 
nARMD patients comparing an every-four-weeks injection 
frequency of bevacizumab therapy to an every-six-weeks or 
every-eight-weeks injection frequency showed no significant 
difference for lower injection frequencies for visual acuity 
and central retinal thickness [26]. In the current non-inferi-
ority study, we aimed to determine whether bevacizumab 
therapy administered every 6 or 8 weeks is also not infe-




This is a secondary analysis of an RCT comparing three 
treatment regimens of bevacizumab (Avastin) for the 
treatment of ARMD on visual acuity and central retinal 
thickness [26]. A total of 191 patients were enrolled in a 
1-year, prospective, open-label RCT which investigated 
the optimal injection frequency of bevacizumab injection 
for ARMD treatment at the Rotterdam Eye Hospital from 
June 2008 to March 2010 (Fig. 1). To be eligible, patients 
had to be at least 65 years old, have a best-corrected visual 
acuity of 20/200 to 20/20 (Snellen equivalent) in the study 
eye as assessed using Early Treatment Diabetic Retinopathy 
Charts (ETDRS), no previous ARMD treatment and active 
leakage. Patients were only treated in one eye. Fluorescein 
angiography (FA) and indocyanine green (ICG) angiogra-
phy were used to observe leakage, and optical coherence 
tomography (OCT) was used to observe the presence of fluid 
[26]. Patients who had other significant ocular disorders, had 
allergies to either FA or ICG dye injections, were immuno-
compromised, using coumarin-derivatives, had experienced 
a clinically significant cerebrovascular accident or myocar-
dial infarction or had a planned ocular surgery during the 
1-year follow-up, were excluded. Written informed consent 
was obtained from all participants. After baseline measure-
ments were completed, all eligible patients were randomized 
to an injection frequency of every 4, 6, or 8 weeks using a 
computer-based 1:1:1 ratio block randomization procedure.
Treatment
Apart from the difference in frequency, treatment regimens 
were comparable among the three groups. At each outpatient 
visit, a dose of 1.25 mg bevacizumab was administered intra-
vitreally. On top of the measures during regular outpatient 
visits, patients were assessed every 12 weeks by best-cor-
rected visual acuity, spectral-domain OCT and funduscopy. 
Monthly checks for adverse events took place by questioning 
patients. Treatment was continuous for 1 year, independent 
of visual acuity change, spectral-domain OCT measures, or 
funduscopy findings. The 4 weeks, 6 weeks, and 8 weeks 
bevacizumab treatment regimens resulted in totals of 13, 9, 
and 7 injections and visits a year, respectively.
Outcome measures
At baseline and at the final follow-up visit, patients were 
asked to complete the National Eye Institute 39-Item Visual 
Function Questionnaire (NEI VFQ-39) [27] and the 36-item 
Medical Outcomes Study Short-Form General Health Sur-
vey (SF-36) [28, 29]. The NEI VFQ-39 assesses vision-
related QoL, while the SF-36 evaluates general QoL. Given 
the nature of the disease, both questionnaires were presented 
in a larger font size and often administered in the presence 
and sometimes with support of a caregiver and/or family 
member.
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Vision‑related quality of life: NEI VFQ‑39
The primary outcome was vision-related QoL, measured 
as the composite score on the NEI VFQ-39 [27]. The NEI 
VFQ-39 consists of a 25-item base set of questions and 14 
supplemental items. All items use a Likert-type scaling 
and five response categories, with occasionally a sixth cat-
egory to opt out, except for two items that have 10 response 
options. Responses are converted into 12 vision-targeted 
multi-item subscales (0–100): general health, general vision, 
ocular pain, near activities, distant activities, social func-
tioning, mental health, role limitations, dependency, driv-
ing, color vision, and peripheral vision. These 12 subscales 
can be summarized as a single composite score. A 10-point 
difference in either the sub-scales or the composite score of 
the NEI VFQ-39 is deemed clinically important, and thus 
considered a clinically meaningful change [30, 31]. The reli-
ability of the NEI VFQ-39 in age-related macular degenera-
tion varies from a Cronbach’s alpha of 0.86 to 0.96 [32, 33].
General quality of life: SF‑36
Another outcome measure was general QoL measured by the 
SF-36 [29]. This is a self-report questionnaire comprising 36 
questions measuring different aspects of general health. All 
items use a Likert based scaling and use two to six response 
options. The responses are converted into eight multi-item 
subscales: physical functioning, role functioning physical, 
bodily pain, general health, vitality, social functioning, role 
functioning emotional, and mental health. These scales 
can be summarized as a psychometrically based ‘physical 
component summary’ (PCS), in which the first four scales 
are most heavily weighted, and a ‘mental component sum-
mary’ (MCS), in which the last four scales are most heav-
ily weighted [34]. These summaries are transformed into 
T-scores with a mean of 50 and standard deviation of 10. 
Higher scores on SF-36 scales indicate a better quality of 
life. The UK version reliability of the physical subscale is 
0.92, and the mental subscale is 0.89 [34]. Following the 
approach provided by Jacobson & Truax, the clinical sig-
nificant change is 7.84 and 9.19 for the respective subscales 
[35].
Data analysis and statistical methods
Differences between dropouts and retained patients were 
analyzed with Student’s t- and chi square-tests. Baseline dif-
ferences for continuous variables between the three groups 
were analyzed with One-way ANOVA with Bonferroni 
correction for pairwise differences. Chi square-tests were 
applied for binary variables and when significant, standard-
ized residuals were evaluated to determine the deviating 
Randomized (n=191)
Allocaon to 4 weeks group (n=64)
Lost to follow-up (n=7)
• Severe Adverse Event (n=4)
• Death (n=2)
• No filled in follow-up 
quesonnaire (n=1) 
Study protocol violaons (n=12)
• Non-compliance (n=8)
• Other therapy indicaon (n=4)
Complete cases (n=45)





Allocaon to 6 weeks group (n=63)
Lost to follow-up (n=1)
• Severe Adverse Event (n=0)
• Death (n=1)
• No filled in follow-up 
quesonnaire (n=0)
Study protocol violaons (n=5)
• Non-compliance (n=4)
• Other therapy indicaon (n=1)
Complete cases (n=57)
All cases included (n=63)
Allocaon to 8 weeks group (n=64)
Lost to follow-up (n=4)
• Severe Adverse Event (n=3)
• Death (n=0)
• No filled in follow-up 
quesonnaire (n=1)
Study protocol violaons (n=7)
• Non-compliance (n=6)
• Other therapy indicaon (n=1)
Complete cases (n=53)
All cases included (n=64)
Fig. 1  CONSORT flow diagram of enrolment, allocation, follow-up and analysis of the every-four-weeks, every-six-weeks, and every-eight-
weeks treatment groups [38]
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groups. The non-inferiority limit for the 6 weeks and 8 
weeks groups comparison with the 4 weeks group was based 
on the 10-point clinical significant difference of the NEI 
VFQ, composite score and the subscales near vision, dis-
tance vision and role limitations. This negative 10-point dif-
ference indicated the lower end of the ‘region of therapeutic 
equivalence’ and, together with the maximum possible dif-
ference, enclosed the ‘region of non-inferiority’ [36]. The 
region of non-inferiority ranged from − 10 to 100. Non-infe-
riority was assumed whenever the 95% confidence interval 
of the difference in change fell entirely within this region 
[36]. Note that only the right-hand side of the distribution 
was relevant, Fig. 2.
In addition, differences between treatment groups were 
tested for the secondary SF-36 subscales. We applied mul-
tilevel linear regression analyses to evaluate differences in 
change in QoL between the three randomization groups. The 
patients formed the upper level, their repeated measures the 
lower level. These analyses can handle data with missing 
time points efficiently, i.e. data of patients without a follow-
up can be included, without a need for imputation. For each 
outcome we applied a separate model. The random parts 
of the models only included the intercept. The fixed parts 
of the models included time (follow-up vs. baseline), cen-
tered baseline score, 6-weeks and 8-week frequencies and 
the interaction of time with baseline, six and eight weeks 
frequencies. The four-week frequency group served as refer-
ence group. In all analyses, gender and age were included as 
control variables.
The study was originally designed to detect differences 
in visual acuity, and subsequently powered with a non-
inferiority limit of seven letters [26]. When testing QOL, a 
power analysis for non-inferiority was performed on the NEI 
VFQ-39 composite score. The clinical important difference 
for the NEI VFQ-39 is 10 and the standard deviation is 20, 
the one-sided alpha was set at 0.05 and power at 0.80, for 
which a sample size of 50 persons per group is needed. This 
implies that the sample size of 63–64 is sufficient.
All other analyses were performed with IBM SPSS ver-
sion 24.0 “IBM Corp. Released 2016. IBM SPSS Statistics 
for Windows, Version 21.0. Armonk, NY: IBM Corp.”
This study was approved by the Erasmus Medical 
Research Ethics Committee (MEC-2007-254) in accordance 
with the Code of Ethics of the World Medical Association 
(Declaration of Helsinki) and was registered in the Dutch 
Trial Register (NTR 1174).
Results
Demographic and clinical characteristics
After randomization, 64 patients were treated in the 4 weeks 
group, 63 in the 6 weeks group, and 64 in the 8 weeks group. 
Treatment arms were well balanced with regard to baseline 
demographic characteristics, visual acuity, and other char-
acteristics of the affected eye (Table 1). However, significant 
baseline differences were present for the NEI VFQ-39 as the 
8 weeks group had lower scores than the 4 weeks group.
Dropouts
Patients lost to follow-up were subdivided based on their 
exit reasons (Table 1). The highest drop-out rate in the 4 
weeks treatment group (29.7%) and the lowest in the 6 weeks 
group (9.5%) significantly differed, p = 0.004. Patients who 
dropped out had significantly worse baseline scores than 
retained patients on the physical component summary of 
the SF-36: t(176) =  − 2.95, p = 0.004 (not in Table 1). No 














Fig. 2  Forest plot of 95% confidence intervals of differences between treatment groups. The sensitivity analysis was based on a matched sample
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NEI VFQ‑39
The changes and differences estimated by the multilevel 
models are presented in Table 2, the total models are pre-
sented in Table 3. Observed differences are presented in 
Appendix 1 and the observed means and standard devia-
tions in Appendix 2. The 95% confidence intervals of the 
difference in change scores showed that the composite 
score interval was well inside the [− 10, 100] point differ-
ence interval that represented the non-inferiority region for 
the three treatment comparisons (Fig. 2). For the subscales 
near activities, distant activities, role limitations, visual 
functioning and socio-emotional functioning the 95% 
confidence intervals of the differences were also entirely 
within the region of non-inferiority. This also barely holds 
for the near activities estimate for gain within 6 weeks 
(10.26) compared to gain within 8 weeks (6.43). This 95% 
confidence interval of − 9.91 to 2.24 is just within the 
limit.
SF‑36
The treatment did not significantly affect the SF-36 com-
ponent summaries. All treatment effects of different injec-
tion frequencies were well within the non-inferiority limits 
(Table 2).
Discussion
To study non-inferiority of a less frequent injection sched-
ule for bevacizumab therapy, we tested QoL in 191 ARMD 
patients who were randomly assigned to receive 1 year 
of continuous treatment with intravitreal bevacizumab 
Table 1  Baseline characteristics
a The treatment eye was defined as the worse-seeing eye when the visual acuity letter score at baseline was 
worse by five or more letters compared to that for the fellow eye. Patients with missing visual acuity (VA) 
scores or similar VA scores within a 5 letter range, were omitted, resulting in n = 53, 55, and 56, respec-
tively [38]
b Higher scores indicate a better quality of life
c In the every 4 weeks group n = 63
d SAE = Severe Adverse Event
e The baseline scores were included in the multilevel model to adjust for potential differences
f The difference was between the every 4–8 weeks p < 0.05 (Bonferroni correction)








Age in years at baseline, mean ± SD 76.5 ± 6.8 77.4 ± 6.7 78.1 ± 6.1 0.436
Gender, male n (%) 18 (28.1) 25 (39.7) 21 (32.8) 0.382
Race, Caucasian n (%) 63 (98.4) 63 (100) 64 (100) 0.369
Visual acuity score ± no. letters 66 ± 12 65 ± 13 62 ± 15 0.230
Total thickness at fovea, µm ± SD 369 ± 85 371 ± 97 371 ± 97 0.990
Patients treated in worse eye, n (%)a 30 (56.6) 31 (56.4) 30 (53.6) 0.955
NEI VFQ-39, mean ± SDb,e
 Composite score 72.0 ± 17.6 67.8 ± 20.0 63.1 ± 19.4 0.032f
 Near activities 60.5 ± 24.2 57.1 ± 24.7 49.4 ± 26.7 0.041f
 Distant activities 67.8 ± 23.6 64.3 ± 25.2 57.9 ± 25.1 0.073
 Role limitations 64.2 ± 25.9 60.2 ± 27.2 52.6 ± 25.5 0.042f
SF-36, mean ± SDb,c,e
 Physical component 44.8 ± 10.9 42.1 ± 11.1 42.2 ± 9.2 0.288
 Mental component 50.9 ± 9.1 51.5 ± 11.5 48.4 ± 11.1 0.239
Lost to follow-up, n (%)
 Exit reason
  SAEd 4 (6.3) 0 (0.0) 3 (4.7) 0.150
  Death 2 (3.1) 1 (1.6) 0 (0.0) 0.364
  Non-compliance 8 (12.5) 4 (6.3) 6 (9.4) 0.495
  No filled in follow-up questionnaire 1 (1.6) 0 (0.0) 1 (1.6) 0.608
  Other therapy indication 4 (6.3) 1 (1.6) 1 (1.6) 0.217
Total 19 (29.7) 6 (9.5) 11 (17.2) 0.013g
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injections every 4, 6, or 8 weeks. In this study we showed 
that 6 weeks and 8 weeks injection regimens were not 
inferior to the four-week regimen in QoL assessments. The 
eight-week regimen was also not inferior to the six-week 
regimen. Thus, regarding patient satisfaction there is no 
objection to reduce the frequency of the injection to eight 
instead of 4 weeks. This is in line with the former results 
of our study group, where no effects of a lower injection 
frequency on visual acuity and central retinal thickness 
were observed [26].
In daily ophthalmic care the fixed regimen as examined 
in this study is not routine clinical practice. The treat-and-
extent regimen is accepted as the preferred practice, in 
which, after an initial induction phase, the next treatment 
interval is extended as long as the patient shows no symp-
toms of relapse. A lower injection frequency may reduce 
the burden for patient and doctor, the chances of injection-
related side effects, and treatment costs. Hereby, the biggest 
fear of extending treatment interval is that in the meanwhile 
the dormant disease will flame up and cause irreversible 
Table 2  Estimated changes in the NEI VFQ-39 and SF-36 scores, age, gender and baseline controlled score
Non-inferiority means that the lower boundary of the 95% CI is not lower than minus 10 for the NEI-VFQ composite score or subscales and p 
values indicate whether the difference of changes is different from zero














p value Estimate [95% 
CI]






2.91 6.59 5.05 3.68 0.094 2.15 0.338 − 1.53 0.474
[− 0.25, 6.07] [3.65, 9.53] [2.04, 8.07] [− 0.63, 8.00] [− 2.26, 6.56] [− 5.75, 2.68]
 Near activi-
ties
8.83 10.26 6.43 1.43 0.650 − 2.41 0.452 − 3.84 0.215
[4.33, 13.34] [6.01, 14.51] [2.10, 10.75] [− 4.76, 7.62] [− 8.71, 3.89] [− 9.91, 2.24]
 Distance 
activities
5.13 5.51 6.80 0.38 0.898 1.66 0.580 1.28 0.656
[0.90, 9.37] [1.56, 9.47] [2.74, 10.85] [− 5.41, 6.17] [− 4.24, 7.56] [− 4.39, 6.60]
 Role limita-
tions
1.63 5.83 6.15 4.21 0.259 4.53 0.234 0.32 0.929




− 0.88 − 0.53 − 0.25 0.35 0.810 0.63 0.670 0.28 0.842
[− 3.00, 1.23] [− 2.49, 1.42] [− 2.26, 1.76] [− 2.52, 3.22] [− 2.29, 3.56] [− 2.52, 3.09]
 Mental com-
ponent
3.20 0.85 2.66 − 2.35 0.103 − 0.54 0.715 1.82 0.201
[1.13, 5.27] [− 1.09, 2.78] [0.66, 4.66] [− 5.18, 0.47] [− 3.42, 2.35] [− 0.97, 4.60]
Table 3  Multilevel VFQ-39 and SF-36 models
NEI VFQ-39 SF-36
Composite score Near activities Distance activities Role limitations Physical compo-
nent
Mental component
Estimate p value Estimate p value Estimate p value Estimate p value Estimate p value Estimate p value
Intercept 67.02  < 0.001 54.70  < 0.001 62.37  < 0.001 58.02  < 0.001 42.94  < 0.001 50.13  < 0.001
Male 2.21 0.024 3.40 0.014 3.36 0.012 3.49 0.030 0.56 0.383 0.21 0.739
Age 0.00 0.991 − 0.09 0.371 − 0.07 0.511 0.00 0.984 0.05 0.303 − 0.08 0.080
Time 2.91 0.071 8.83  < 0.001 5.13 0.018 1.63 0.551 − 0.88 0.412 3.20 0.003
Baseline 1.00  < 0.001 0.99  < 0.001 0.99  < 0.001 0.99  < 0.001 1.00  < 0.001 1.00  < 0.001
Time × baseline − 0.32  < 0.001 − 0.29  < 0.001 − 0.31  < 0.001 − 0.38  < 0.001 − 0.28  < 0.001 − 0.54  < 0.001
Every 6 weeks − 0.21 0.885 − 0.25 0.907 − 0.21 0.917 − 0.37 0.881 − 0.14 0.887 0.09 0.920
Time × 6 weeks 3.68 0.094 1.43 0.650 0.38 0.898 4.21 0.259 0.35 0.810 − 2.35 0.103
Every 8 weeks − 0.13 0.930 − 0.14 0.946 − 0.20 0.920 − 0.18 0.942 − 0.12 0.900 0.16 0.869
Time × 8 weeks 2.15 0.338 − 2.41 0.452 1.66 0.580 4.53 0.234 0.63 0.670 − 0.54 0.715
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vision loss. The current challenge is to find the right balance 
in treating, waiting and adjusting. Another way to reduce 
burden is to determine whether the initial 4 weeks injec-
tion interval used with treat-and-extend could be perhaps 
6 or 8 weeks. This current study implicates that there is 
room to investigate this statement. For an 8 weeks pro re 
nata, on demand, versus a 4 weeks pro re nata regimen no 
significant difference was shown [39]. In consideration of 
these results, low frequency injections (in particular every 
8 weeks) of intravitreal bevacizumab should not be withheld 
from patients with nARMD.
Strengths and limitations
The every-four-weeks regimen group had the highest drop-
out rate. However, it is unlikely that this higher drop-out 
rate jeopardizes the conclusion, as drop-outs tended to have 
the same baseline values. The main reasons for treatment 
discontinuation in all groups were compliance‐related study 
visit violations. The noncompliance is not only an issue in 
this study but a problem also in clinical practice [37]. In this 
study, we see a slightly higher, though not significant, non-
adherence rate with the most rigorous treatment schedule, 
which may be a justification for considering a lower treat-
ment frequency as alternative, as this may increase patient 
compliance. But where some see frequent visits as a hassle, 
others will see it as a welcome social benefit. In the end, 
again, more personalized care might be the answer.
Imbalances were found in the vision-related QoL baseline 
scores. Principally these differences are a coincidental result 
of randomization, but as it might have affected the results, 
the positive effect of the treatment was larger in the eight-
week group, we corrected for baseline in the model. In this 
analysis the interaction between baseline and time confirms 
the influence of an imbalanced baseline. Apparently, patients 
with lower baseline scores on average have larger increase 
in QoL. This could logically be a result of regression to the 
mean. This same situation occurred in the previous study 
where the difference of 4 letters on baseline was equalized 
at follow-up [26]. It is obviously more difficult to improve 
more if you already have a high QoL.
Conclusion
Non-inferiority of the 6 and 8 weeks frequencies to 4 weeks 
was demonstrated on vision-related and general QoL in 
patients with nARMD. These results are in line with previ-
ously published results of these frequency injections. Lower 
injection frequency may reduce burden, side effects, and 
treatment costs. In consideration of these results, 6 and in 
particular 8-week frequency injections of intravitreal beva-
cizumab could be considered in patients with nARMD.
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